A

Azenta

Automated cold-chain sample management and multiomics

Overview

Azenta provides life sciences solutions focused on end-to-end sample management and genomic services. It combines automated ultra-cold storage, cryogenics, consumables, instruments, and repository services with genomic services like sequencing and gene synthesis through its GENEWIZ brand. The company offers an integrated stack of hardware, consumables, software (LIMS like Limfinity and Freezer Pro), and services to collect, store, and analyze biological samples across their lifecycle. Its end-to-end portfolio and recurring revenue, supported by acquisitions, differentiate it from competitors and aim to speed up drug development, clinical research, and advanced cell therapies by preserving sample integrity from collection to analysis.

Work here?Claim your company

About Azenta

Simplify's Rating
Why Azenta is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & AnalyticsEnterprise SoftwareBiotechnologyHealthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Burlington, MA

Founded

1978

Get referred to Azenta

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • Fiscal 2026 revenue reached $621.7 million, with Q4 organic growth of 2%.
  • Fiscal 2027 guidance of $648 million-$660 million signals another year of growth.
  • Azenta bought SynPlexity for $15 million and licensed Elegen on October 28.

What critics are saying

  • Multiomics organic revenue fell 1% in Q4 2026, dragging growth.
  • Rosen Law Firm is pursuing securities claims after Marotta's August 22 resignation.
  • If Elegen integration stumbles, GENEWIZ loses exclusivity and Azenta's growth thesis breaks.

What makes Azenta unique

  • Azenta pairs ultra-cold sample storage with genomics, creating recurring revenue across workflows.
  • GENEWIZ adds sequencing, gene synthesis, and AI-ready synthetic biology capabilities.
  • The 2026 Elegen license gives exclusive DNA synthesis technology and regional manufacturing leverage.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$13.6M

Above

Industry Average

Funded Over

1 Rounds

IPO funding comparison data is currently unavailable. We're working to provide this information soon!
IPO Funding Comparison Coming Soon

Benefits

  • Flexible Work Hours

Stock Price

Growth & Insights and Company News

6 month growth

-3%

1 year growth

0%

2 year growth

-3%
Yahoo Finance
Nov 12th, 2026
Azenta shares jump 44% in 90 days on $621.7M revenue, but still look 29% overvalued

Azenta reported fiscal 2026 revenue of $621.7 million and guided to $648 million to $660 million from continuing operations in 2027. The company also announced two deals to strengthen its GENEWIZ and Multiomics businesses, covering gene synthesis and synthetic biology services. Its shares have risen 44.21% over 90 days, and one-year total shareholder return is 58.92%. Over five years, however, total shareholder return has fallen 59.05%. The stock closed at $48.90. A Simply Wall St analyst consensus puts fair value at $37.80, which would make the shares 29% overvalued, while its discounted cash flow model points to $23.67. Risks include weak Multiomics demand in North America and governance investigations.

AlphaStreet
Nov 11th, 2026
Azenta Q4 2026 EPS tops expectations, revenue up 5%.

Azenta Q4 2026 EPS tops expectations, revenue up 5%. Impressive Beat. Azenta, Inc. (AZTA) posted Q4 2026 adjusted EPS of $0.28, topping Wall Street's $0.11 estimate by 154.5%, demonstrating operational leverag... AlphaStreet Newsdesk powered by AlphaStreet Intelligence AZTA | EPS $0.28 vs $0.11 est (+154.5%) | Rev $167.1M | Net Income $6.8M Stock $40.48 (-1.1%) Impressive Beat. Azenta, Inc. (AZTA) posted Q4 2026 adjusted EPS of $0.28, topping Wall Street's $0.11 estimate, demonstrating operational leverage. The company generated $167.1M in revenue for the quarter, up 5.0% from $159.2M in Q4 2025, with the company earning $6.8M in net income. The medical instruments and supplies company's stock traded down 1.1% to $40.48 following the release, suggesting investors may be focused on forward guidance rather than the substantial quarterly outperformance. Discover more Stock market trends Read Daily News Quality of Beat. The earnings beat appears to reflect genuine operational improvement rather than pure cost management, as revenue growth of 5.0% year-over-year accompanied the bottom-line outperformance. Organic revenue growth was +2.0% for the quarter, indicating the top-line expansion included both organic growth and likely contribution from acquisitions or favorable foreign exchange. Management noted that "4th quarter revenue was $167 million, up 5% as reported and 2% organically, with SMS organic growth of 4% and multi-omics down 1%," providing insight into the mixed performance across business lines. Segment Performance. Sample Management Solutions led with $94.0M in revenue, up 9.0% year-over-year, representing the stronger performing division within Azenta's segments. The SMS segment's 4% organic growth rate, as highlighted by management, outpaced the company-wide organic growth of 2.0% and demonstrates the division's ability to capture market share in sample storage and management solutions. The multi-omics business declined 1% organically, creating a headwind that the company will need to address to accelerate overall growth. Forward Guidance. Revenue guidance for the full year was set at $648.0M to $660.0M, providing investors with a framework for fiscal 2027 expectations. Management stated that "for fiscal 2027, we expect organic revenue growth of 3% to 5%," suggesting the company anticipates modest acceleration from the 2.0% organic growth delivered in Q4 2026. The guidance range implies continued steady expansion in the medical instruments space, though the organic growth projection suggests a measured outlook rather than aggressive market share gains. Analyst Positioning. Wall Street consensus stands at 5 buy, 4 hold, 0 sell, reflecting a moderately bullish stance on Azenta's prospects despite the muted stock reaction to quarterly results. The absence of sell ratings indicates no major structural concerns among the analyst community covering the medical instruments provider, though the split between buy and hold recommendations suggests some uncertainty about the pace of growth acceleration. What to Watch: The ability to stabilize and return the multi-omics segment to positive organic growth will be critical to achieving the upper end of fiscal 2027 revenue guidance, while Sample Management Solutions must sustain its momentum to offset any continued weakness in the smaller division. This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content. Discover more Financial market analysis Earnings call transcripts Stock market research

MarketBeat
Nov 11th, 2026
Azenta (NASDAQ:AZTA) hits new 52-week high following strong earnings.

Azenta (NASDAQ:AZTA) hits new 52-week high following strong earnings. November 11, 2026 Key points. * Azenta shares reached a new 52-week high of $47.72 after reporting quarterly adjusted EPS of $0.28, beating the $0.11 analyst estimate, and revenue of $167.09 million, above the $160.16 million consensus. * For fiscal 2027, the company forecast revenue of $648 million-$660 million, above analyst expectations, and projected 3%-5% organic growth with adjusted EBITDA margin expansion of about 200-250 basis points. * Rosen Law Firm is investigating potential securities claims related to allegations of misleading business information; the inquiry raises legal and reputational uncertainty but is not a finding of wrongdoing. * Five stocks to consider instead of Azenta. Shares of Azenta, Inc. (NASDAQ:AZTA - Get Free Report) hit a new 52-week high during trading on Wednesday after the company announced better than expected quarterly earnings. The company traded as high as $47.72 and last traded at $47.4580, with a volume of 204,979 shares changing hands. The stock had previously closed at $40.48. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.17. The firm had revenue of $167.09 million for the quarter, compared to analysts' expectations of $160.16 million. Azenta had a negative net margin of 20.63% and a positive return on equity of 1.18%. Top Azenta stories. * For fiscal Q4 2026, Azenta reported adjusted EPS of $0.28, versus analysts' $0.11 estimate, and revenue of $167.09 million, above the $160.16 million consensus. Revenue grew 5% year over year as reported and 2% organically. * Fiscal 2027 revenue guidance of $648 million to $660 million is above the $632.4 million consensus. Azenta also expects 3%-5% organic revenue growth and adjusted EBITDA margin expansion of about 200-250 basis points, signaling expectations for continued growth and improved profitability. * Rosen Law Firm said it is investigating potential securities claims tied to allegations that Azenta may have provided materially misleading business information. The inquiry could create legal and reputational uncertainty, but the announcement describes allegations, not a finding of misconduct. Analyst upgrades and downgrades. A number of equities analysts recently issued reports on AZTA shares. Wall Street Zen lowered Azenta from a "buy" rating to a "hold" rating in a report on Sunday, October 18th. Weiss Ratings raised Azenta from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, August 26th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $37.00 price target on shares of Azenta in a research report on Monday, September 14th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $41.20. Discover more MarketBeat All Access MarketBeat Portfolio Tracker MarketBeat Research Tools Institutional trading of Azenta. Hedge funds have recently bought and sold shares of the company. Global Retirement Partners LLC boosted its holdings in shares of Azenta by 82.3% during the third quarter. Global Retirement Partners LLC now owns 771 shares of the company's stock worth $27,000 after purchasing an additional 348 shares during the period. Heritage Family Offices LLP acquired a new position in Azenta in the 3rd quarter valued at approximately $31,000. State of Wyoming acquired a new position in Azenta in the 1st quarter valued at approximately $38,000. Integrated Wealth Concepts LLC purchased a new stake in Azenta in the 2nd quarter worth approximately $39,000. Finally, Allworth Financial LP purchased a new stake in Azenta in the 2nd quarter worth approximately $48,000. 99.08% of the stock is owned by hedge funds and other institutional investors. Azenta stock performance. The business's 50 day simple moving average is $35.64 and its 200-day simple moving average is $28.47. The company has a market cap of $2.08 billion, a price-to-earnings ratio of -17.18 and a beta of 1.47. Azenta company profile. Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Azenta, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Azenta wasn't on the list. While Azenta currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power. Continue following MarketBeat

The Cerbat Gem
Nov 1st, 2026
Azenta (NASDAQ: AZTA) buys SynPlexity and licenses Elegen DNA tech for GENEWIZ.

Azenta (NASDAQ: AZTA) buys SynPlexity and licenses Elegen DNA tech for GENEWIZ. What happened. Azenta, Inc. (NASDAQ: AZTA) took an exclusive license to Elegen Corp.'s gene synthesis technology and bought SynPlexity Inc. to expand its GENEWIZ business. Both agreements were signed Oct. 28, and the SynPlexity purchase closed at signing. Azenta announced them in an Oct. 30 press release. The Elegen arrangement has two parts, a Technology, Equipment and License Agreement and a Master Services and Supply Agreement. Azenta says they work together to support GENEWIZ gene synthesis and regional production capacity. The filing treats SynPlexity as a separate deal. Both are meant to support the company's DNA synthesis work. Trey Martin, President, Multiomics at Azenta, said the investments "strengthen the competitive position of GENEWIZ" and are "key to accelerating our growth." Key numbers. | Metric | Latest | Change | Source | | Perpetual-license conversion payment (plus any unpaid license fees) | $25 million | / | SEC 8-K | | Expected capital deployment under Elegen agreements, low end | approximately $32 million | / | SEC 8-K | | Expected capital deployment under Elegen agreements, high end | approximately $71 million | / | SEC 8-K | | Initial term of the License Agreement | 5 years | / | SEC 8-K | | Window to exercise conversion option, after execution | 12 to 18 months | / | SEC 8-K | How the Elegen license works. Azenta and its controlled affiliates hold an exclusive, royalty-free license to Elegen's patents and know-how on gene synthesis and cell-free cloning. They can make and sell gene synthesis products as a service to third-party customers worldwide. Elegen keeps some rights. It can supply its platform and consumables to customers for their internal research, development and limited manufacturing. It can also perform specified existing customer contracts. The initial term is five years and can be extended by mutual agreement. Between 12 and 18 months after signing, Azenta can pay $25 million, plus any unpaid license fees, to convert the license to an irrevocable, perpetual, exclusive, royalty-free one. If the agreement expires without conversion, the product license generally continues as perpetual, fully paid-up and non-exclusive. Under the supply agreement, Elegen will provide its proprietary consumables for the licensed platform and related services. These include access to its facility for training and process development. For up to five years and subject to conditions, the license also gives Azenta certain rights over specified proposed changes of control of Elegen. Those rights also cover transfers of its relevant business or technology rights. What the two deals add to GENEWIZ. The press release describes the Elegen platform as a cell-free DNA synthesis platform designed to improve DNA quality, delivery speed and manufacturing scalability. Its compact production workflows let Azenta add regional capacity close to customers as demand requires. SynPlexity contributes pooled gene assembly technology that provides thousands of full-length gene variants in a single library. Azenta says that lets researchers build and test large numbers of candidates, including AI-generated designs. Azenta plans to fold the acquired technology and expertise into its GENEWIZ synthesis portfolio. Why it matters. OptimistFi has argued that Azenta creates value if sample management and multiomics stay differentiated enough to turn modest growth into durable operating leverage. These deals add gene synthesis technology to the multiomics side of the business, so they strengthen that case. The Elegen commitment is a range, not a fixed sum. Azenta expects to deploy approximately $32 million to approximately $71 million, and the top of that range is more than double the bottom. The outcome depends on future equipment purchases. It also depends on whether Azenta converts to perpetual rights, which is its choice and not an obligation. The filing is direct about the risks. Azenta lists its ability to complete technology transfer, validate and scale the licensed platform, and integrate the acquired technology and personnel. It says actual results could differ materially. Azenta also depends on Elegen for technology, consumables, equipment, software and support. Without conversion, exclusivity does not carry past the license term. What's next. Azenta said additional details will be provided on its fourth quarter fiscal 2026 earnings call. It plans to file the full Elegen agreements as exhibits to its Form 10-Q for the quarter ending Dec. 31, 2026. The conversion window opens 12 months after the Oct. 28 signing and closes at 18 months. Paying $25 million would lock in exclusivity. Letting the term run out would leave Azenta with a non-exclusive license. From optimistfi perps. Sources. * Azenta, Inc. Form 8-K dated Oct. 28, 2026 - Items 1.01, 7.01 and 8.01: the Elegen License and Supply Agreements and the SynPlexity acquisition. * Azenta press release, Exhibit 99.1, Oct. 30, 2026 - Announcement of the strategic investments to advance GENEWIZ gene synthesis capabilities. Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research. Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.

Associated Press
Oct 30th, 2026
Azenta shares fall 12% after CEO resigns; Rosen Law Firm prepares investor class action

Rosen Law Firm says it is investigating potential securities claims for shareholders of Azenta (NASDAQ: AZTA). It alleges the company may have issued materially misleading business information to investors. Azenta told the US Securities and Exchange Commission (SEC) on August 24, 2026, that John P. Marotta resigned as president, chief executive officer, and board member on August 22, 2026. Its stock fell 12% on August 24. The law firm is preparing a class action to recover investor losses. It says investors who bought Azenta securities may be eligible for compensation under a contingency fee arrangement, with no out-of-pocket costs.

Recently Posted Jobs

Sign up to get curated job recommendations

Azenta is Hiring for 76 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs